Brief: Oncorus Appoints Eric Rubin To Its Board Of Directors
Brief: Oncorus Inc - Announced Nomination Of Its First Synthetic Viral Rna Immunotherapy Clinical Candidates, Oncr-021 And Oncr-788
Oncorus Inc reports results for the quarter ended in March - Earnings Summary
Brief: Oncorus Reports Q4 2020 Results
U.S. STOCKS ON THE MOVE-Bumble, HubSpot, Amicus, NexImmune
Oncorus Inc: Drops on discounted pricing of share offering
Brief: Oncorus Announces Pricing Of Public Offering Of Common Stock
Brief: Oncorus Inc Files Preliminary Prospectus Related To Offering Of 3 Million Shares Of Common Stock - SEC Filing
Brief: Oncorus Inc Announces Publication Of Preclinical Data Supporting Clinical Development Of ONCR-177
Brief: Oncorus Inc To Build Gmp Viral Immunotherapy Clinical Manufacturing Facility In Andover, Mass
Brief: Oncorus Appoints Scott Canute To Its Board Of Directors
Brief: Oncorus Reports Third Quarter 2020 Financial Results And Provides Business Highlights
Brief: James Flynn Reports 13.04% Stake In Oncorus Inc
Brief: Citadel Advisors Llc Reports A 8.5% Passive Stake In Oncorus Inc As Of October 2, 2020 - SEC Filing
Oncorus Inc: Rises 3% in Nasdaq debut
Brief: Oncorus Inc Shares Open 3.3% Above IPO Price In Debut On Nasdaq
NASDAQ RESUMED AT 11:42 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 04:02 AM
Brief: Oncorus Announces Pricing Of IPO